Guideline on the clinical development of medicinal products for the treatment of Autism Spectrum Disorder





Most readers of this blog are in North America and I think this will be by far the largest market for any new drugs approved for autism.

An even bigger market by population (508 million vs 354 million) is the European Union, where the drug regulator is now developing guidance for those developing new treatments for autism.  They are asking for comments.

The only people really qualified to give comments are those with some experience of treating autism, very few of whom live in Europe.

Regardless of where you live, I would suggest that the doctors and researchers who read this blog take a look at the short guideline document and pass on any comments they may have to the European Medicines Agency.  

For everyone else, I do not suppose they expect to get comments from lay people, but why not go ahead and surprise them?

The obvious comment would be to hurry up, but there are many more constructive comments that can be made. 



The Press Release:




The Draft Guidance Document:- 








Comments

Popular posts from this blog

Cinnamon (Cinnamaldehyde), Mast Cells (Allergy) & Autism

PolyPill for Autism - Part 2

Autism Pathology as a Venn Diagram